A pilot program in Taiwan has introduced Hospital-at-Home (HaH), an alternative care model providing hospital-level treatment in patients’ homes. A study evaluated HaH outcomes for patients with pneumonia, urinary tract infections, or soft tissue infections from August 2024 to January 2025, involving 69 HaH patients and a matched group of 246 hospitalized patients. Results showed that HaH patients had a significantly shorter length of stay and lower medical costs. Specifically, HaH patients had an adjusted odds ratio (OR) of 0.53 for length of stay and 0.18 for medical expenditure, both statistically significant. Additionally, 73.9% of HaH patients transitioned to home healthcare, compared to 7.3% of traditional patients, with a 100% satisfaction rate. There were no significant differences in emergency department visits or rehospitalization rates between the two groups. The findings suggest that HaH not only enhances patient outcomes and satisfaction but also reduces healthcare costs, indicating its potential for broader implementation in Taiwan and its contribution to healthcare resilience.